Hospital-acquired pneumonia

Revision as of 20:24, 5 September 2012 by Priyamvada Singh (talk | contribs)
Jump to navigation Jump to search

Pneumonia Main Page

Hospital-acquired pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hospital-Acquired Pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Diagnostic Algorithm

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hospital-acquired pneumonia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hospital-acquired pneumonia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hospital-acquired pneumonia

CDC onHospital-acquired pneumonia

Hospital-acquired pneumonia in the news

Blogs on Hospital-acquired pneumonia

Directions to Hospitals Treating Hospital-acquired pneumonia

Risk calculators and risk factors for Hospital-acquired pneumonia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hospital-acquired pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Treatment

Medical Therapy

Prevention

Differential diagnosis

Treatment

Usually initial therapy is empirical.[1] If sufficient reason to suspect influenza one might consider amantadine or rimantadine. In case of legionellosis erythromicin or fluoroquinolone.[2]

A third generation cephalosporin (ceftazidime) + carbapenems (imipenem) + beta lactam & beta lactamase inhibitors (piperacillin/tazobactum)

References

Template:WH Template:WS